Stock Market Impact: Eli Lilly (NYSE:LLY) shares increased 4.5% after the company presented Phase 3 data on its obesity drug retatrutide at the American Diabetes Association conference.
Clinical Trial Details: Two Phase 3 studies were disclosed:
TRANSCEND‑T2D‑1 evaluated retatrutide in treatment‑naïve type 2 diabetes patients.
TRIUMPH‑1 evaluated the drug in overweight or obese patients without diabetes; the 4 mg dose achieved weight‑loss outcomes surpassing those of semaglutide in the STEP 1 trial and within 4 % of the maximum 15 mg tirzepatide dose observed in the SURMOUNT 1 study.
Safety Profile: Analysts noted the presentations did not raise any new safety concerns.
Commercial Outlook: At an investor event, Lilly indicated its long‑acting amylin analog eloralintide could become one of its largest‑ever Phase 3 programs, with combination data with tirzepatide expected later in 2026.
Market Share Dynamics: Tirzepatide, marketed as Mounjaro (diabetes) and Zepbound (obesity), continues to gain market share against Novo Nordisk’s Ozempic and Wegovy in the United States and, as of Q1 2026, internationally.
Publication Note: Headline numbers for the first Phase 3 study were released in late May, but the tight timeline prevented concurrent journal publication.
